WU
The startup develops radioimmunotherapy drugs that utilize targeted radiolabeled antibodies to selectively destroy cancer cells while mitigating treatment resistance in tumor tissues. This approach enhances the efficacy of cancer treatment by harnessing the immune system's capabilities alongside radiotherapy.
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops radioimmunotherapy drugs that utilize targeted radiolabeled antibodies to selectively destroy cancer cells while mitigating treatment resistance in tumor tissues. This approach enhances the efficacy of cancer treatment by harnessing the immune system's capabilities alongside radiotherapy.